ChemoCentryx Inc

-17.03 (-61.95%)
5:18:07 PM EDT: $10.84 +0.38 (+3.63%)

ChemoCentryx Announces FDA Acceptance Of Avacopan NDA For Anca-Associated Vasculitis Treatment

Published: 09/17/2020 12:40 GMT
ChemoCentryx Inc (CCXI) - Chemocentryx Announces FDA Acceptance of the Avacopan New Drug Application (nda) for the Treatment of Anca-associated Vasculitis.
Chemocentryx Inc - FDA Sets PDUFA Goal Date of July 7, 2021.
Chemocentryx Inc - FDA Also Indicated That It May But Has Not Yet Determined Whether to Hold an Advisory Committee Meeting to Discuss Application.